-
Something wrong with this record ?
Identification of disease phenotypes in acetylcholine receptor-antibody myasthenia gravis using proteomics-based consensus clustering
C. Nelke, CB. Schroeter, S. Barman, F. Stascheit, L. Masanneck, L. Theissen, N. Huntemann, S. Walli, D. Cengiz, V. Dobelmann, A. Vogelsang, M. Pawlitzki, S. Räuber, FF. Konen, T. Skripuletz, HP. Hartung, S. König, A. Roos, A. Meisel, SG. Meuth, T. Ruck
Language English Country Netherlands
Document type Journal Article
NLK
Directory of Open Access Journals
from 2014
PubMed Central
from 2014
Open Access Digital Library
from 2014-11-01
Open Access Digital Library
from 2014-01-01
Open Access Digital Library
from 2014-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2014
- MeSH
- Complement Activation MeSH
- Autoantibodies * blood immunology MeSH
- B-Lymphocytes metabolism immunology MeSH
- Adult MeSH
- Phenotype * MeSH
- Middle Aged MeSH
- Humans MeSH
- Myasthenia Gravis * blood diagnosis immunology metabolism MeSH
- Proteome MeSH
- Proteomics * methods MeSH
- Receptors, Cholinergic * immunology metabolism MeSH
- Aged MeSH
- Cluster Analysis MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
BACKGROUND: The clinical heterogeneity of myasthenia gravis (MG), an autoimmune disease defined by antibodies (Ab) directed against the postsynaptic membrane, constitutes a challenge for patient stratification and treatment decision making. Novel strategies are needed to classify patients based on their biological phenotypes aiming to improve patient selection and treatment outcomes. METHODS: For this purpose, we assessed the serum proteome of a cohort of 140 patients with anti-acetylcholine receptor-Ab-positive MG and utilised consensus clustering as an unsupervised tool to assign patients to biological profiles. For in-depth analysis, we used immunogenomic sequencing to study the B cell repertoire of a subgroup of patients and an in vitro assay using primary human muscle cells to interrogate serum-induced complement formation. FINDINGS: This strategy identified four distinct patient phenotypes based on their proteomic patterns in their serum. Notably, one patient phenotype, here named PS3, was characterised by high disease severity and complement activation as defining features. Assessing a subgroup of patients, hyperexpanded antibody clones were present in the B cell repertoire of the PS3 group and effectively activated complement as compared to other patients. In line with their disease phenotype, PS3 patients were more likely to benefit from complement-inhibiting therapies. These findings were validated in a prospective cohort of 18 patients using a cell-based assay. INTERPRETATION: Collectively, this study suggests proteomics-based clustering as a gateway to assign patients to a biological signature likely to benefit from complement inhibition and provides a stratification strategy for clinical practice. FUNDING: CN and CBS were supported by the Forschungskommission of the Medical Faculty of the Heinrich Heine University Düsseldorf. CN was supported by the Else Kröner-Fresenius-Stiftung (EKEA.38). CBS was supported by the Deutsche Forschungsgemeinschaft (DFG-German Research Foundation) with a Walter Benjamin fellowship (project 539363086). The project was supported by the Ministry of Culture and Science of North Rhine-Westphalia (MODS, "Profilbildung 2020" [grant no. PROFILNRW-2020-107-A]).
Brain and Mind Center University of Sydney Sydney NSW Australia
Department of Neurology Charité Universitätsmedizin Berlin Berlin Germany
Department of Neurology Hannover Medical School Hannover Germany
Department of Neurology Medical Faculty Heinrich Heine University Duesseldorf Duesseldorf Germany
Department of Neurology Palacky University Olomouc Olomouc Czech Republic
Department of Neuropaediatrics Neuromuscular Centre Universitätsmedizin Essen Essen Germany
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24019859
- 003
- CZ-PrNML
- 005
- 20241024111051.0
- 007
- ta
- 008
- 241015e20240702ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ebiom.2024.105231 $2 doi
- 035 __
- $a (PubMed)38959848
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Nelke, Christopher $u Department of Neurology, Medical Faculty, Heinrich Heine University Duesseldorf, Duesseldorf, Germany
- 245 10
- $a Identification of disease phenotypes in acetylcholine receptor-antibody myasthenia gravis using proteomics-based consensus clustering / $c C. Nelke, CB. Schroeter, S. Barman, F. Stascheit, L. Masanneck, L. Theissen, N. Huntemann, S. Walli, D. Cengiz, V. Dobelmann, A. Vogelsang, M. Pawlitzki, S. Räuber, FF. Konen, T. Skripuletz, HP. Hartung, S. König, A. Roos, A. Meisel, SG. Meuth, T. Ruck
- 520 9_
- $a BACKGROUND: The clinical heterogeneity of myasthenia gravis (MG), an autoimmune disease defined by antibodies (Ab) directed against the postsynaptic membrane, constitutes a challenge for patient stratification and treatment decision making. Novel strategies are needed to classify patients based on their biological phenotypes aiming to improve patient selection and treatment outcomes. METHODS: For this purpose, we assessed the serum proteome of a cohort of 140 patients with anti-acetylcholine receptor-Ab-positive MG and utilised consensus clustering as an unsupervised tool to assign patients to biological profiles. For in-depth analysis, we used immunogenomic sequencing to study the B cell repertoire of a subgroup of patients and an in vitro assay using primary human muscle cells to interrogate serum-induced complement formation. FINDINGS: This strategy identified four distinct patient phenotypes based on their proteomic patterns in their serum. Notably, one patient phenotype, here named PS3, was characterised by high disease severity and complement activation as defining features. Assessing a subgroup of patients, hyperexpanded antibody clones were present in the B cell repertoire of the PS3 group and effectively activated complement as compared to other patients. In line with their disease phenotype, PS3 patients were more likely to benefit from complement-inhibiting therapies. These findings were validated in a prospective cohort of 18 patients using a cell-based assay. INTERPRETATION: Collectively, this study suggests proteomics-based clustering as a gateway to assign patients to a biological signature likely to benefit from complement inhibition and provides a stratification strategy for clinical practice. FUNDING: CN and CBS were supported by the Forschungskommission of the Medical Faculty of the Heinrich Heine University Düsseldorf. CN was supported by the Else Kröner-Fresenius-Stiftung (EKEA.38). CBS was supported by the Deutsche Forschungsgemeinschaft (DFG-German Research Foundation) with a Walter Benjamin fellowship (project 539363086). The project was supported by the Ministry of Culture and Science of North Rhine-Westphalia (MODS, "Profilbildung 2020" [grant no. PROFILNRW-2020-107-A]).
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a myasthenia gravis $x krev $x diagnóza $x imunologie $x metabolismus $7 D009157
- 650 12
- $a receptory cholinergní $x imunologie $x metabolismus $7 D011950
- 650 12
- $a autoprotilátky $x krev $x imunologie $7 D001323
- 650 12
- $a proteomika $x metody $7 D040901
- 650 12
- $a fenotyp $7 D010641
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a shluková analýza $7 D016000
- 650 _2
- $a proteom $7 D020543
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a B-lymfocyty $x metabolismus $x imunologie $7 D001402
- 650 _2
- $a aktivace komplementu $7 D003167
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Schroeter, Christina B $u Department of Neurology, Medical Faculty, Heinrich Heine University Duesseldorf, Duesseldorf, Germany
- 700 1_
- $a Barman, Sumanta $u Department of Neurology, Medical Faculty, Heinrich Heine University Duesseldorf, Duesseldorf, Germany
- 700 1_
- $a Stascheit, Frauke $u Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany
- 700 1_
- $a Masanneck, Lars $u Department of Neurology, Medical Faculty, Heinrich Heine University Duesseldorf, Duesseldorf, Germany
- 700 1_
- $a Theissen, Lukas $u Department of Neurology, Medical Faculty, Heinrich Heine University Duesseldorf, Duesseldorf, Germany
- 700 1_
- $a Huntemann, Niklas $u Department of Neurology, Medical Faculty, Heinrich Heine University Duesseldorf, Duesseldorf, Germany
- 700 1_
- $a Walli, Sara $u Department of Neurology, Medical Faculty, Heinrich Heine University Duesseldorf, Duesseldorf, Germany
- 700 1_
- $a Cengiz, Derya $u Department of Neurology, Medical Faculty, Heinrich Heine University Duesseldorf, Duesseldorf, Germany
- 700 1_
- $a Dobelmann, Vera $u Department of Neurology, Medical Faculty, Heinrich Heine University Duesseldorf, Duesseldorf, Germany
- 700 1_
- $a Vogelsang, Anna $u Department of Neurology, Medical Faculty, Heinrich Heine University Duesseldorf, Duesseldorf, Germany
- 700 1_
- $a Pawlitzki, Marc $u Department of Neurology, Medical Faculty, Heinrich Heine University Duesseldorf, Duesseldorf, Germany
- 700 1_
- $a Räuber, Saskia $u Department of Neurology, Medical Faculty, Heinrich Heine University Duesseldorf, Duesseldorf, Germany
- 700 1_
- $a Konen, Felix F $u Department of Neurology, Hannover Medical School, Hannover, Germany
- 700 1_
- $a Skripuletz, Thomas $u Department of Neurology, Hannover Medical School, Hannover, Germany
- 700 1_
- $a Hartung, Hans-Peter $u Department of Neurology, Medical Faculty, Heinrich Heine University Duesseldorf, Duesseldorf, Germany; Brain and Mind Center, University of Sydney, Sydney NSW, Australia; Department of Neurology, Palacky University Olomouc, Olomouc, Czech Republic
- 700 1_
- $a König, Simone $u Core Unit Proteomics, Interdisciplinary Center for Clinical Research, Medical Faculty, University of Münster, Münster, Germany
- 700 1_
- $a Roos, Andreas $u Department of Neuropaediatrics, Neuromuscular Centre, Universitätsmedizin Essen, Essen, Germany
- 700 1_
- $a Meisel, Andreas $u Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany
- 700 1_
- $a Meuth, Sven G $u Department of Neurology, Medical Faculty, Heinrich Heine University Duesseldorf, Duesseldorf, Germany
- 700 1_
- $a Ruck, Tobias $u Department of Neurology, Medical Faculty, Heinrich Heine University Duesseldorf, Duesseldorf, Germany. Electronic address: Tobias.Ruck@med.uni-duesseldorf.de
- 773 0_
- $w MED00190061 $t EBioMedicine $x 2352-3964 $g Roč. 105 (20240702), s. 105231
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38959848 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241015 $b ABA008
- 991 __
- $a 20241024111045 $b ABA008
- 999 __
- $a ok $b bmc $g 2202208 $s 1231832
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 105 $c - $d 105231 $e 20240702 $i 2352-3964 $m EBioMedicine $n EBioMedicine $x MED00190061
- LZP __
- $a Pubmed-20241015